Omnix CV Tablet is a combination antibiotic formulation containing Cefixime 200 mg and Clavulanic Acid 125 mg, designed for the treatment of a broad spectrum of bacterial infections. Cefixime, a third-generation cephalosporin, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, thereby effectively targeting susceptible Gram-positive and Gram-negative pathogens. Clavulanic Acid serves as a beta-lactamase inhibitor, enhancing the efficacy of Cefixime by preventing enzymatic degradation of the antibiotic, particularly against beta-lactamase-producing resistant strains. This synergistic combination is indicated for the management of respiratory tract infections, urinary tract infections, otitis media, pharyngitis, tonsillitis, and uncomplicated skin and soft tissue infections. Omnix CV Tablet is administered orally and should be used under medical supervision with dosage adjusted according to infection severity and patient-specific factors such as renal function. Common adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and alterations in liver enzyme levels. Caution is advised in patients with a history of penicillin or cephalosporin allergy. The use of Omnix CV Tablet should be guided by susceptibility testing and local antimicrobial guidelines to minimize the development of resistance and ensure optimal therapeutic outcomes.